Gujarat Kidney & Super Speciality Ltd
Incorporated in 2019, Gujarat Kidney and Super Speciality Limited specializes in providing multispeciality healthcare services.[1]
- Market Cap ₹ 1,391 Cr.
- Current Price ₹ 176
- High / Low ₹ 210 / 98.2
- Stock P/E 87.9
- Book Value ₹ 32.0
- Dividend Yield 0.00 %
- ROCE 14.5 %
- ROE 11.1 %
- Face Value ₹ 2.00
Pros
- Company is expected to give good quarter
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 172 days.
- Working capital days have increased from 55.7 days to 91.1 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Hospital
Part of BSE Healthcare BSE IPO Nifty IPO
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| 0 | 5 | 40 | 82 | 101 | |
| 0 | 3 | 24 | 55 | 74 | |
| Operating Profit | -0 | 2 | 17 | 27 | 27 |
| OPM % | 41% | 41% | 33% | 26% | |
| 0 | 1 | 0 | 1 | 2 | |
| Interest | 0 | 0 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 3 | 5 | 5 |
| Profit before tax | -0 | 2 | 13 | 21 | 21 |
| Tax % | 0% | 25% | 26% | 21% | |
| -0 | 2 | 10 | 17 | 17 | |
| EPS in Rs | -0.00 | 0.49 | 1.66 | 1.97 | 2.14 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 119% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 1058% |
| TTM: | 37% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 16% |
| Last Year: | 11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.20 | 0.20 | 11 | 16 |
| Reserves | 0 | 11 | 15 | 237 |
| 0 | 6 | 8 | 29 | |
| 4 | 4 | 21 | 16 | |
| Total Liabilities | 4 | 21 | 55 | 298 |
| 0 | 14 | 31 | 129 | |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 12 |
| 4 | 7 | 24 | 157 | |
| Total Assets | 4 | 21 | 55 | 298 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 0 | 1 | 14 | -4 | |
| 0 | 0 | -18 | -214 | |
| 0 | -0 | 6 | 228 | |
| Net Cash Flow | 0 | 1 | 2 | 11 |
| Free Cash Flow | 0 | 2 | -5 | -98 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 0% | 70% | 99% | 21% |
Ratios
Consolidated / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 321 | 138 | 172 | |
| Inventory Days | ||||
| Days Payable | ||||
| Cash Conversion Cycle | 321 | 138 | 172 | |
| Working Capital Days | 100 | -24 | 91 | |
| ROCE % | 19% | 52% | 14% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2026 | |
|---|---|---|---|
| Average Bed Occupancy Rate % ・Standalone data |
|
||
| Average Revenue per Occupied Bed INR ・Standalone data |
|||
| Operational Beds beds ・Standalone data |
|||
| Acquired Ownership Stake - Ashwini Medical Centre % ・Standalone data |
|||
| Acquired Ownership Stake - Harmony Medicare Private Limited % ・Standalone data |
|||
| Acquired Ownership Stake - Parekhs Hospital Private Limited % ・Standalone data |
|||
| Acquired Ownership Stake - Patel Multispeciality Hospital and ICU % ・Standalone data |
|||
| Acquired Ownership Stake - Patel Pharmacy % ・Standalone data |
|||
| Acquisition Cost - Ashwini Medical Centre INR ・Standalone data |
|||
| Acquisition Cost - Harmony Medicare Private Limited INR ・Standalone data |
|||
| Acquisition Cost - Parekhs Hospital Private Limited INR ・Standalone data |
|||
| Acquisition Cost - Patel Multispeciality Hospital and ICU INR ・Standalone data |
|||
| Acquisition Cost - Patel Pharmacy INR ・Standalone data |
|||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results For The Quarter Ended September 30, 2026.
- Board meets November 4, 2026 to consider Q2 FY2027 unaudited standalone and consolidated results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Submitted Regulation 74(5) confirmation certificate for shares dematerialised during quarter ended September 30, 2026.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
- Gujarat Kidney held 7th AGM on 28 Sept 2026; shareholders approved financials, director appointments, remuneration revisions and related-party transactions.
- Closure of Trading Window
Business Profile[1]
Gujarat Kidney and Super Speciality Limited is a regional healthcare operator in central Gujarat, running a chain of mid-sized multi-speciality hospitals focused on secondary and tertiary care.